HanAll BioPharma Co., Ltd.
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1973-11-20
- Employees
- -
- Market Cap
- -
- Website
- http://www.hanall.co.kr
Clinical Trials
16
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
Efficacy and Safety of Leuprolide Acetate 45 mg in Subjects With Central Precocious Puberty
- Conditions
- CPP
- Interventions
- Drug: Eligard® 45 mg
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- HanAll BioPharma Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT06926933
- Locations
- 🇰🇷
Korea University Ansan Hospital, Ansan, Korea, Republic of
🇰🇷Jeonbuk National University Hospital, Jeonju, Korea, Republic of
🇰🇷Chosun University Hospital, Kwangju, Korea, Republic of
A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease
- First Posted Date
- 2024-05-06
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- HanAll BioPharma Co., Ltd.
- Target Recruit Count
- 750
- Registration Number
- NCT06400589
- Locations
- 🇺🇸
HanAll Site #1, Delray Beach, Florida, United States
A Study Assessing the Safety of Oral ATH-399A in Healthy Adult Participants
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- HanAll BioPharma Co., Ltd.
- Target Recruit Count
- 76
- Registration Number
- NCT06088784
- Locations
- 🇨🇦
Syneos Quebec Canada, Quebec, Canada
A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry Eye
- Conditions
- Dry Eye
- Interventions
- Drug: PlaceboDrug: 0.25% Tanfanercept Ophthalmic Solution
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- HanAll BioPharma Co., Ltd.
- Target Recruit Count
- 260
- Registration Number
- NCT05109702
- Locations
- 🇺🇸
Cornea & Cataract Consultants of Arizona, Phoenix, Arizona, United States
🇺🇸Global Research Management, Glendale, California, United States
🇺🇸Eye Research Foundation, Inc., Newport Beach, California, United States
A Study to Assess Efficacy and Safety of HL036 in Subjects With Dry Eyes
- Conditions
- Dry Eye
- First Posted Date
- 2019-02-19
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- HanAll BioPharma Co., Ltd.
- Target Recruit Count
- 637
- Registration Number
- NCT03846453
- Locations
- 🇺🇸
Cornea and Cataract Consultants of Arizona, Phoenix, Arizona, United States
🇺🇸Eye Research Foundation, Newport Beach, California, United States
🇺🇸East West Eye Institute, Torrance, California, United States
- Prev
- 1
- 2
- 3
- 4
- Next